Study of AFP464 +/- Faslodex in ER + Breast Cancer

• Status: Terminated
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tigris Pharmaceuticals
• Treatments: Estradiol; Fulvestrant

Criteria

Inclusion Criteria:

• proven breast cancer, ER+ status; progression on an aromatase inhibitor; measurable disease or evaluable disease with serum CA27.29>=50 U/mL; adequate bone marrow, liver and renal function; DLco grade 0 or 1.

Exclusion Criteria:

• HER2 positive, thoracic radiotherapy or symptomatic pulmonary disease, brain metastases,